In Brief: Pharmavene
Executive Summary
Pharmavene: Licenses Carbatrol (carbamazepine) anti-epileptic to Elan subsidiary Athena, which hopes to market Carbatrol to compete with Ciba's recently approved twice-daily tablet carbamazepine formulation Tegretol XR,, according to a July 5 IPO "red herring" prospectus. Pharmavene's NDA for its sustained-release capsule formulation of carbamazepine was submitted April 3. The proposed offering is for 2.2 mil. shares of common stock at an estimated price of $10-$12 per share...
Pharmavene: Licenses Carbatrol (carbamazepine) anti-epileptic to Elan subsidiary Athena, which hopes to market Carbatrol to compete with Ciba's recently approved twice-daily tablet carbamazepine formulation Tegretol XR,, according to a July 5 IPO "red herring" prospectus. Pharmavene's NDA for its sustained-release capsule formulation of carbamazepine was submitted April 3. The proposed offering is for 2.2 mil. shares of common stock at an estimated price of $10-$12 per share.... |